Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Lucentis has been approved to treat people in Scotland with vision impairment as a result of diabetic macular oedema (VI-DMO), pharmaceutical company Novartis has announced today (December 10). The drug, which has been approved by the
Scottish Medicines Consortium (SMC), is the first medicine to be licensed to treat the sight threatening condition.
In its decision, the SMC acknowledged the drug?s ?superior? clinical effectiveness over laser therapy, which is currently offered to treat VI-DMO. Laser therapy is not suitable for everyone and has only been shown to stabilise vision. While Lucentis, also known as ranibizumab, has been found to significantly improve visual acuity over 12 months.
http://www.optometry.co.uk/news-and-features/news/?article=4112
Scottish Medicines Consortium (SMC), is the first medicine to be licensed to treat the sight threatening condition.
In its decision, the SMC acknowledged the drug?s ?superior? clinical effectiveness over laser therapy, which is currently offered to treat VI-DMO. Laser therapy is not suitable for everyone and has only been shown to stabilise vision. While Lucentis, also known as ranibizumab, has been found to significantly improve visual acuity over 12 months.
http://www.optometry.co.uk/news-and-features/news/?article=4112